Rebecca Kumar, MD
Infectious Disease · Washington, DCNPI 1437544517
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 87.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $5,574 and has fallen 86.7% since, to $740 in 2024.
Across 24 payments — averaging $486.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- Astrazeneca UK Limited$1K
- Takeda Pharmaceuticals U.S.A., Inc.$128
- Gilead$78
Across 33 payments — averaging $14,752 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$340K
- Pfizer$145K
- GSK$1K
What the payments were for
- Consulting fees$2,96625%
- Speaking & faculty fees$5,65048%
- Travel & lodging$2,39721%
- Food & beverage$6606%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $10,190 |
| Astrazeneca UK Limited | 9 | $1,277 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $128 |
| Gilead | 1 | $78 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVUSHELD$7,594
How this compares
$11,673 in reported general payments places this provider in the 85th percentile of 74 infectious disease providers in District of Columbia.
See all infectious disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Washington
- Jesse GoodmanWashington$1.8M
- Theo HodgeWashington$1M
- Robert GasserWashington$922K
- Princy KumarWashington$270K
- Jose ChavezWashington$254K
- Linda NabhaWashington$60K
- Gebeyehu TeferiWashington$25K
- Jose BordonWashington$12K
- Jeffrey MurrayWashington$8K
- David DiemertWashington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.